Nautilus Biotechnology, Inc.
$2.58
-3.7%Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -5.5).
Valuation inputs: P/E -5.5, earnings yield N/A, momentum -3.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -37.6%, ROIC -35.7%).
Profitability stack: net margin 0.0%, ROE -37.6%, ROIC -35.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +17.9%, momentum -3.7%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Nautilus Biotechnology, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Nautilus Biotechnology, Inc. Fair Value Envelope
No Revenue Data
NAUT has not reported any revenue values in the available annual periods.
Nautilus Biotechnology, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
NAUT has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
NAUT has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
NAUT has not reported any net profit margin values in the available annual periods.
Nautilus Biotechnology, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Nautilus Biotechnology, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Nautilus Biotechnology, Inc. Street Expectations Map
Wall Street analysts project that NAUT stock may see slight declines over the coming 12 months. The consensus 1-year price target stands at 2.50, with estimates ranging from a low of 2.50 to a high of 2.50.
The consensus 1-year price target stands at 2.50, with estimates ranging from a low of 2.50 to a high of 2.50.
Analyst Consensus Analysis
Upside Potential
Fair value territory. Stock trading near consensus target suggests limited near-term catalysts. Focus on fundamental developments.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Risk-Reward Profile
Balanced risk-reward. Upside and downside potential relatively symmetric. Suitable for moderate risk tolerance with conviction in thesis.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Efficient pricing: Stock trading at fair value with strong consensus suggests market has priced in expectations. Look for fundamental inflection points or new catalysts to drive meaningful moves.
Nautilus Biotechnology, Inc. Insider Positioning
During the last 12 months, insiders have purchased $376K worth of NAUT shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
25.0K
65.24K
0
0.00
+65K
+$65K
6-9 Months
87.5K
62.99K
0
0.00
+63K
+$63K
9-12 Months
361.5K
247.80K
0
0.00
+248K
+$248K
Top Buyers
Patel Sujal M
Director, 10 Percent Owner, Officer: Ceo, President, And Secretary
$201K
Mcilwain Matthew S
Director
$31K
Nazem Farzad
Director
$31K
Epperly Melissa B,
Director
$31K
Posard Matthew L.
Director
$31K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $376K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
NAUT has not reported any dividend yield values in the available annual periods.
naut Dividend History
Learning Layer
Related Guides
Build conviction on NAUT by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.